These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 18819144)
41. Oral sirolimus after bare metal stent implantation: a glimpse to the future. Mieres J Catheter Cardiovasc Interv; 2011 Jan; 77(1):158-9. PubMed ID: 20931667 [No Abstract] [Full Text] [Related]
42. Sirolimus- versus paclitaxel-eluting stents for unselected patients with coronary artery disease. Park SJ Catheter Cardiovasc Interv; 2011 Jan; 77(1):13-4. PubMed ID: 21181967 [No Abstract] [Full Text] [Related]
43. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. Ramana RK; Ronan A; Cohoon K; Homan D; Sutherland J; Steen L; Liu J; Loeb H; Lewis BE Catheter Cardiovasc Interv; 2008 Jun; 71(7):886-93. PubMed ID: 18412238 [TBL] [Abstract][Full Text] [Related]
44. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study. Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498 [TBL] [Abstract][Full Text] [Related]
45. Paclitaxel-eluting balloons for sirolimus-eluting stent restenosis. Alfonso F; Dutary J; Paulo M; Pérez-Vizcayno MJ JACC Cardiovasc Interv; 2011 Jun; 4(6):716; author reply 716-7. PubMed ID: 21700261 [No Abstract] [Full Text] [Related]
46. Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion. Tcheng JE; Zidar DA JACC Cardiovasc Interv; 2009 Dec; 2(12):1266-8. PubMed ID: 20129554 [No Abstract] [Full Text] [Related]
47. Sirolimus-Coated Balloons for In-Stent Restenosis: The Evolution of PCI. Finn AV Circ Cardiovasc Interv; 2024 Sep; 17(9):e014464. PubMed ID: 39051114 [No Abstract] [Full Text] [Related]
48. Transition from bare metal to drug eluting stenting in contemporary US practice: effect on incidence and predictors of clinically driven target lesion revascularization. Jonas M; Resnic FS; Levin AD; Arora N; Rogers CD Catheter Cardiovasc Interv; 2007 Aug; 70(2):175-83. PubMed ID: 17630659 [TBL] [Abstract][Full Text] [Related]
49. Revascularization for ischemic LV dysfunction: stents or surgery? Thomas M Catheter Cardiovasc Interv; 2007 Jul; 70(1):34. PubMed ID: 17580365 [No Abstract] [Full Text] [Related]
50. Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial. Loh JP; Stella PR; Sangiorgi G; Silber S; Stahnke S; von Strandmann RP; Torguson R; Waksman R Cardiovasc Revasc Med; 2014 Jan; 15(1):23-8. PubMed ID: 24444473 [TBL] [Abstract][Full Text] [Related]
51. DES in CTO: cosmetic or clinical benefit. Goyal BK Catheter Cardiovasc Interv; 2009 May; 73(6):780. PubMed ID: 19370758 [No Abstract] [Full Text] [Related]
52. Impact of lesion calcification on clinical and angiographic outcome after sirolimus-eluting stent implantation in real-world patients. Kawaguchi R; Tsurugaya H; Hoshizaki H; Toyama T; Oshima S; Taniguchi K Cardiovasc Revasc Med; 2008; 9(1):2-8. PubMed ID: 18206630 [TBL] [Abstract][Full Text] [Related]
53. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). Spaulding C; Teiger E; Commeau P; Varenne O; Bramucci E; Slama M; Beatt K; Tirouvanziam A; Polonski L; Stella PR; Clugston R; Fajadet J; de Boisgelin X; Bode C; Carrié D; Erglis A; Merkely B; Hosten S; Cebrian A; Wang P; Stoll HP; Henry P JACC Cardiovasc Interv; 2011 Jan; 4(1):14-23. PubMed ID: 21251624 [TBL] [Abstract][Full Text] [Related]
54. The efficacy of drug-eluting stents in women: a window of opportunity. Jacobs AK JACC Cardiovasc Interv; 2009 Jul; 2(7):611-3. PubMed ID: 19628182 [No Abstract] [Full Text] [Related]
55. Vulnerable plaque inside stent. Cho JM; Sohn IS; Kim CJ; Jang IK JACC Cardiovasc Imaging; 2011 Apr; 4(4):430-1. PubMed ID: 21492819 [No Abstract] [Full Text] [Related]
56. The Kounis syndrome in everolimus-eluting stents and paclitaxel-eluting stents. Kounis NG; Giannopoulos S; Goudevenos JA Catheter Cardiovasc Interv; 2010 Dec; 76(7):1076-7; author reply 1078. PubMed ID: 21086494 [No Abstract] [Full Text] [Related]
57. If I've heard it once, I've heard it (not yet) a hundred times. Butman SM Catheter Cardiovasc Interv; 2011 Mar; 77(4):502. PubMed ID: 21351224 [No Abstract] [Full Text] [Related]
58. Repeat in-stent restenosis of drug-eluting stents in a bifurcation treated successfully with kissing drug eluting balloons. Abergel E; Beyar R; Roguin A Cardiovasc Revasc Med; 2013; 14(2):106-8. PubMed ID: 23195308 [TBL] [Abstract][Full Text] [Related]
59. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries. Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW; JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464 [TBL] [Abstract][Full Text] [Related]
60. Unprotected left main coronary artery stenting with zotarolimus (Endeavor) drug-eluting stents: a single center retrospective experience. Simard T; Hibbert B; Chong AY; Ruchin P; Le May M; Labinaz M; Froeschl M; So D; Glover C; Marquis JF; O'Brien E Catheter Cardiovasc Interv; 2012 Aug; 80(2):E15-22. PubMed ID: 21805580 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]